Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A new TRAIL in Alzheimer's disease therapy.

Literature DB >> 25564490

A new TRAIL in Alzheimer's disease therapy.

Dan Frenkel¹.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2015 PMID： 25564490 PMCID： PMC4441083 DOI： 10.1093/brain/awu334

Source DB: PubMed Journal: Brain ISSN： 0006-8950 Impact factor: 13.501

× No keyword cloud information.

13 in total

Review 1. Immunology and immunotherapy of Alzheimer's disease.

Authors: Howard L Weiner; Dan Frenkel
Journal: Nat Rev Immunol Date: 2006-05 Impact factor: 53.106

2. TRAIL is expressed in the brain cells of Alzheimer's disease patients.

Authors: Daniela Uberti; Giuseppina Cantarella; Fabio Facchetti; Alessia Cafici; Giuseppe Grasso; Renato Bernardini; Maurizio Memo
Journal: Neuroreport Date: 2004-03-22 Impact factor: 1.837

3. Blocking TRAIL-DR5 signaling with soluble DR5 reduces delayed neuronal damage after transient global cerebral ischemia.

Authors: Min Cui; Limei Wang; Xiaohong Liang; Xuelian Ma; Yugang Liu; Mingfeng Yang; Kejing Liu; Xinbing Wei; Zhiqiang Zhou; Youhai H Chen; Wensheng Sun
Journal: Neurobiol Dis Date: 2010-03-30 Impact factor: 5.996

Review 4. Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease.

Authors: M T Heneka; M P Kummer; S Weggen; B Bulic; G Multhaup; L Münter; M Hüll; T Pflanzner; C U Pietrzik
Journal: Curr Alzheimer Res Date: 2011-03 Impact factor: 3.498

Review 5. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?

Authors: Tony Wyss-Coray
Journal: Nat Med Date: 2006-09 Impact factor: 53.440

6. Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer's disease.

Authors: Giuseppina Cantarella; Giulia Di Benedetto; Daniela Puzzo; Lucia Privitera; Carla Loreto; Salvatore Saccone; Salvatore Giunta; Agostino Palmeri; Renato Bernardini
Journal: Brain Date: 2014-12-02 Impact factor: 13.501

Review 7. Deciphering the molecular basis of memory failure in Alzheimer's disease.

Authors: Dominic M Walsh; Dennis J Selkoe
Journal: Neuron Date: 2004-09-30 Impact factor: 17.173

Review 8. Immunotherapy for Alzheimer's disease.

Authors: Martin R Farlow; Jared R Brosch
Journal: Neurol Clin Date: 2013-05-18 Impact factor: 3.806

Review 9. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).

Authors: Avi Ashkenazi; Pamela Holland; S Gail Eckhardt
Journal: J Clin Oncol Date: 2008-07-20 Impact factor: 44.544

A new TRAIL in Alzheimer's disease therapy.

Review 1. Immunology and immunotherapy of Alzheimer's disease.

2. TRAIL is expressed in the brain cells of Alzheimer's disease patients.

3. Blocking TRAIL-DR5 signaling with soluble DR5 reduces delayed neuronal damage after transient global cerebral ischemia.

Review 4. Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease.

Review 5. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?

6. Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer's disease.

Review 7. Deciphering the molecular basis of memory failure in Alzheimer's disease.

Review 8. Immunotherapy for Alzheimer's disease.

Review 9. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).

10. Neutralization of TRAIL death pathway protects human neuronal cell line from beta-amyloid toxicity.

1. Evidence for a Pan-Neurodegenerative Disease Response in Huntington's and Parkinson's Disease Expression Profiles.

Review 2. Clinical perspectives of TRAIL: insights into central nervous system disorders.

3. Robust Sampling of Defective Pathways in Alzheimer's Disease. Implications in Drug Repositioning.

4. Regulatory T Cell-Derived TRAIL Is Not Required for Peripheral Tolerance.